Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/eps-holdings-inc">EPS Holdings</a> is a key player in the Japanese Contract Research Organization (CRO) market, offering a comprehensive suite of services for pharmaceutical and medical device development, including clinical trial support, site management, and sales services.</li>
 <li>The company faces a challenging environment characterized by declining profitability and negative growth in key financial metrics over the last three to five years, despite a growing domestic market driven by increased R&amp;D outsourcing.</li>
 <li>Future success will depend on navigating intense competition from both global and domestic CROs, adapting to the increasing complexity of drug development, and capitalizing on its strategic focus on being a healthcare solutions provider, particularly leveraging its Japan-China business corridor.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
EPS Holdings is a key player in the Japanese Contract Research Organization (CRO) market, offering a comprehensive suite of services for pharmaceutical and medical device development, including clinical trial support, site management, and sales services.
  The company faces a challenging environment characterized by declining profitability and negative growth in key financial metrics over the last three to five years, despite a growing domestic market driven by increased R&amp;D outsourcing.
  Future success will depend on navigating intense competition from both global and domestic CROs, adapting to the increasing complexity of drug development, and capitalizing on its strategic focus on being a healthcare solutions provider, particularly leveraging its Japan-China business corridor.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: EPS Holdings (4282 JP) - Aug 2026

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

The Tokyo Stock Exchange (TSE) calculates Free-Float Weight (FFW) for each listed company and uses this value as a key component of TOPIX Index Calculation. For companies with "low liquidity" the FFW will be multiplied by a fixed liquidity factor of 0.75 to derive the final FFW used for index calculation. This affects both TSE-1 incumbents and new entrants (depending on the date of entry). Every April, the application of this liquidity factor is reviewed by the TSE for all TSE1 constituents. Last April, 71 constituents saw their liquidity factors removed causing an increase in their respective FFWs used for index calculation resulting in a TOPIX upweight.This situation opens up interesting opportunities for a basket trade. Below is a discussion regarding the key details of TSE's FFW Calculation Methodology and the candidate stocks which could potentially experience a change in the application of the liquidity factor (including some surprisingly big names).

The Tokyo Stock Exchange (TSE) calculates Free-Float Weight (FFW) for each listed company and uses this value as a key component of TOPIX Index Calculation. For companies with "low liquidity" the FFW will be multiplied by a fixed liquidity factor of 0.75 to derive the final FFW used for index calculation. This affects both TSE-1 incumbents and new entrants (depending on the date of entry). Every April, the application of this liquidity factor is reviewed by the TSE for all TSE1 constituents. Last April, 71 constituents saw their liquidity factors removed causing an increase in their respective FFWs used for index calculation resulting in a TOPIX upweight.This situation opens up interesting opportunities for a basket trade. Below is a discussion regarding the key details of TSE's FFW Calculation Methodology and the candidate stocks which could potentially experience a change in the application of the liquidity factor (including some surprisingly big names).   

TOPIX Index Upweights: The Big April Basket 2021

Doing bespoke work since 2002....., Custom Products Group

Patrick Hansen

Doing bespoke work since 2002.....

Custom Products Group

Custom Products was started 14 years ago at Lehman Brothers by current co-founder Patrick Hansen, CFA. After 3 years at Lehman, Patrick moved the team to Macquarie Securities where Simon Rigney (co-founder) joined. 3 years ago we took Custom Products independent. 

Our core strength can be summed up three words. 1- Customization - we have very little off the shelf products and most work is done on a one on one bespoke basis. 2- Speed - We pride ourselves in our ability to get requests back to the client very quickly. 3- Confidentiality - We do not redistribute. There is no grace period where we wait a week and then mass blast. Any request stops with that client.

Thematic (Sector/Industry)

We know that historically there has been a lot of leakage leading into Earnings Season. In a different life, I remember Fuji Photo calling me in and given me a preview of the earnings results 2 weeks before the actual announcement. It may not happen as much now in the large-cap space, so we took a look at the small-cap space with very little coverage to see if there are movements in consensus.

We know that historically there has been a lot of leakage leading into Earnings Season. In a different life, I remember Fuji Photo calling me in and given me a preview of the earnings results 2 weeks before the actual announcement. It may not happen as much now in the large-cap space, so we took a look at the small-cap space with very little coverage to see if there are movements in consensus.

Japanese Small-Cap Names with Consensus Changes Leading into Earning Season....

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

The suggestion of government orchestration against <a href="https://www.smartkarma.com/entities/8979" target="_blank" data-smartkarma-citation="entities:8979:1">Ono</a>’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the Nikkei that the Japanese Health Ministry is considering setting rules on new drug usage during this fiscal year, starting with <a href="https://www.smartkarma.com/entities/8979" target="_blank" data-smartkarma-citation="entities:8979:1">Ono</a>’s Opdivo and <a href="https://www.smartkarma.com/entities/6091" target="_blank" data-smartkarma-citation="entities:6091">Astellas</a>’s Repatha. Patients may be limited to those who can see certain impact from the treatment, which in turn would mean the drug could only be prescribed at those institutions with the facilities to check…

The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the Nikkei that the Japanese Health Ministry is considering setting rules on new drug usage during this fiscal year, starting with Ono’s Opdivo and Astellas’s Repatha. Patients may be limited to those who can see certain impact from the treatment, which in turn would mean the drug could only be prescribed at those institutions with the facilities to check…

Opdivo Singled Out in Government Rule Change

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Last week, the founder and Chairman of <a href="https://www.smartkarma.com/entities/eps-holdings-inc" target="_blank" data-smartkarma-citation="entities:13246:1" rel="noopener">EPS Holdings (4282 JP)</a> announced an MBO to take the company private. In <a href="https://www.smartkarma.com/insights/another-too-cheap-mbo-as-founder-takes-out-eps" target="_blank" data-smartkarma-citation="insights:52208" rel="noopener">Another Too-Cheap MBO as Founder Takes Out EPS</a> I discussed the details of the MBO and Tender Offer and noted that it was "too cheap."The stock traded briefly through terms at the open of trading on Monday 31 May - the first day it could trade freely post-announcement. Today, it traded briefly through terms on a spike, settled back, and then rose into the close, as the two-day 5-minute chart below shows. <section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/210/483/original/Screenshot+2021-06-01+at+6.43.23+PM.png?1622544595" class="editor-image img-responsive" data-smartkarma-image-id="210483"></figure></section>Separately, I heard that there was some talk of "a higher price."I do not have the full story or the content but one has to be careful of the details.

Last week, the founder and Chairman of EPS Holdings (4282 JP) announced an MBO to take the company private. In Another Too-Cheap MBO as Founder Takes Out EPS I discussed the details of the MBO and Tender Offer and noted that it was "too cheap."The stock traded briefly through terms at the open of trading on Monday 31 May - the first day it could trade freely post-announcement. Today, it traded briefly through terms on a spike, settled back, and then rose into the close, as the two-day 5-minute chart below shows. Separately, I heard that there was some talk of "a higher price."I do not have the full story or the content but one has to be careful of the details.

EPS MBO Is Cheap. Too Cheap. But Be Careful Of Your Assumptions

Japan

EPS Holdings, Inc. provides clinical testing services to contract research organizations (CROs) who are in the pharmaceutical industry in Japan. The Company's services range from planning, monitoring, and analyzing study and clinical testing for development of new drugs. EPS also develops systems and provides data management as well as patent registration.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

EPS Holdings (4282 JP)

Primer: EPS Holdings (4282 JP) - Aug 2026

EPS Holdings is a key player in the Japanese Contract Research Organization (CRO) market, offering a comprehensive suite of services for...

αSK Primers

TOPIX Index Upweights: The Big April Basket 2021

TOPIX does an annual exercise to adjust Liquidity Factor. The time for trades around that is upon us. This insight looks at the best trade around...

Janaghan Jeyakumar, CFA

Japanese Small-Cap Names with Consensus Changes Leading into Earning Season....

We know that historically there has been a lot of leakage leading into Earnings Season. In a different life, I remember Fuji Photo calling me in...

Custom Products Group

Opdivo Singled Out in Government Rule Change

The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...

Pelham Smithers Associates

EPS MBO Is Cheap. Too Cheap. But Be Careful Of Your Assumptions

The EPS Holding (8242 JP) MBO is too cheap. Lots too cheap. But it is NOT because management asked for JPY 2100/share. There are good reasons for...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)